References
- Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al, for the LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; In press http://dx.doi.org/10.1016/S0140-6736(12)61770-X; PMID: 23141813
- Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; In press http://dx.doi.org/10.1016/S0140-6736(12)61771-1; PMID: 23141812
- Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012; 126:2408 - 17; http://dx.doi.org/10.1161/CIRCULATIONAHA.112.144055; PMID: 23129602
- Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, et al. Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. J Am Coll Cardiol 2012; 60:1888 - 98; http://dx.doi.org/10.1016/j.jacc.2012.08.986; PMID: 23083772
- Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). European Multidisciplinary Cancer Conference, Stockholm, Sweden, September 23-27, 2011; abstract 5001.